Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erlotinib Prevention of Oral Cancer (EPOC).

Trial Profile

Erlotinib Prevention of Oral Cancer (EPOC).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Mouth neoplasm
  • Focus Therapeutic Use
  • Acronyms EPOC
  • Most Recent Events

    • 25 Sep 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 22 Sep 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top